BerandaAXGN • NASDAQ
add
AxoGen, Inc Common Stock
$32,73
Setelah Jam Perdagangan Normal:(0,092%)-0,030
$32,70
Tutup: 31 Des, 19.30.05 GMT-5 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$32,73
Rentang hari
$32,46 - $33,34
Rentang tahun
$9,22 - $34,24
Kapitalisasi pasar
1,51Â M USD
Volume Rata-Rata
908,32Â rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 60,08Â jt | 23,51% |
Biaya operasional | 44,08Â jt | 19,94% |
Penghasilan bersih | 708,00Â rb | 138,11% |
Margin laba bersih | 1,18 | 130,89% |
Penghasilan per saham | 0,12 | 71,43% |
EBITDA | 3,64Â jt | 159,77% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 35,79Â jt | 45,91% |
Total aset | 216,40Â jt | 12,72% |
Total liabilitas | 95,60Â jt | 3,26% |
Total ekuitas | 120,80 jt | — |
Saham yang beredar | 46,12 jt | — |
Harga terhadap nilai buku | 12,49 | — |
Tingkat pengembalian aset | 2,27% | — |
Tingkat pengembalian modal | 2,56% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | 708,00Â rb | 138,11% |
Kas dari operasi | 3,22Â jt | -17,38% |
Kas dari investasi | -3,75Â jt | 24,98% |
Kas dari pembiayaan | 2,39Â jt | 318,53% |
Perubahan kas bersih | 1,87Â jt | 454,08% |
Arus kas bebas | 3,45Â jt | -3,94% |
Tentang
Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available allograft approved by the Food and Drug Administration for clinical use. Wikipedia
Didirikan
2002
Kantor pusat
Situs
Karyawan
452